A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

NCT02864290 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

43

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to lack of efficacy.

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: ASP1235

Sponsor

Astellas Pharma Global Development, Inc.